BRIEF-Syros Announces Clinical Updates And 2022 Goals To Support Its Advancement To A Fully Integrated Biopharmaceutical Company
* SYROS ANNOUNCES CLINICAL UPDATES AND 2022 GOALS TO SUPPORT ITS ADVANCEMENT TO A FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY
* SYROS PHARMACEUTICALS INC (SYRS) - EXPECTS TO REPORT DATA FROM THREE CLINICAL TRIALS ACROSS HEMATOLOGY AND SELECTIVE CDK INHIBITOR PROGRAMS IN 2022
* SYROS PHARMACEUTICALS INC (SYRS) - NOW EXPECTS TO INITIATE PHASE 1 SINGLE AGENT TRIAL OF SY-5609 IN HEMATOLOGIC MALIGNANCIES IN 2H 2022
* SYROS PHARMACEUTICALS INC (SYRS) - EXPECTS TO NOMINATE DEVELOPMENT CANDIDATE FROM CDK12 PROGRAM IN 2H 2022 Source text for Eikon: Further company coverage: